Spyre Therapeutics Inc is a clinical stage biotechnology company pioneering long acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease and rheumatic diseases. The company focuses on extending the half life of monoclonal antibodies through Fc domain modifications known as YTE substitutions and formulating them as high concentration citrate free preparations for subcutaneous administration. Its pipeline comprises product candidates targeting α4β7 TL1A and IL23 both as monotherapies and as fixed dose combinations such as SPY120 SPY130 and SPY230. Spyre advances these agents through platform trials including the SKYLINE Phase 2 platform trial in ulcerative colitis evaluating monotherapies and pairwise combinations and the SKYWAY Phase 2 basket trial in rheumatoid arthritis psoriatic arthritis and axial spondyloarthritis evaluating its anti TL1A candidate SPY072. As of December 31 2025 the company employed 102 full time staff and maintained its principal executive offices in Waltham Massachusetts. Spyre’s strategy rests on three pillars advancing next generation monotherapies evaluating paradigm changing IBD combinations and expanding its anti‑TL1A program into additional rheumatic indications.

Spyre Therapeutics does not yet generate product revenue because all of its candidates remain in clinical development. The company’s income derives from licensing agreements and collaboration arrangements such as those with Paragon for its α4β7 TL1A and IL23 programs which may include upfront payments milestone payments and royalties on future net sales. In addition Spyre has financed its operations through public offerings and private placements as disclosed in its financial statements though the filing does not specify exact amounts. The firm allocates the majority of its resources to research and development covering preclinical studies clinical trial conduct manufacturing outsourcing and intellectual property protection. General and administrative expenses support corporate functions investor relations and regulatory compliance. Until a product receives regulatory approval Spyre’s revenue will continue to depend on non product sources.

Spyre Therapeutics competes in the biologics market for immune mediated diseases where several large pharmaceutical companies have established therapies. Approved tumor necrosis factor antagonists such as Humira Remicade and Simponi interleukin 12/23 and interleukin 23 inhibitors including Stelara Skyrizi Omvoh and Tremfya α4β7 antagonist Entyvio JAK inhibitors like Xeljanz and Rinvoq and S1P1 receptor modulators such as Zeposia and Velsipity represent the current standard of care. In addition multiple entities are developing next generation TL1A antibodies for inflammatory bowel disease and rheumatic diseases notably Merck’s tulisokibart and Roche/Roivant’s afimkibart. Spyre differentiates itself through its engineering of long acting antibodies that aim to enable quarterly or twice annual subcutaneous dosing reducing the treatment burden for patients. The company also pursues fixed dose combinations that pair distinct mechanisms such as α4β7 with TL1A or IL23 potentially delivering additive or superior efficacy compared with monotherapy. Market data cited in the filing indicate that approximately 2.4 million individuals in the United States suffer from inflammatory bowel disease with about 70,000 new diagnoses each year. Rheumatoid arthritis affects more than 1.5 million people in the US psoriatic arthritis approximately 0.8 million and axial spondyloarthritis an estimated 3 million though only around 1 million are diagnosed. These prevalence figures underscore the sizable patient population that Spyre hopes to serve with its investigational therapies.

The company’s customers are primarily patients living with inflammatory bowel disease such as ulcerative colitis and Crohn’s disease and patients with rheumatic diseases including rheumatoid arthritis psoriatic arthritis and axial spondyloarthritis. These individuals receive care from gastroenterologists, rheumatologists, and other specialists in academic medical centers, community hospitals, and outpatient infusion clinics. Spyre also interacts with clinical trial sites, contract research organizations, and laboratory vendors that support the development and testing of its product candidates. Should any of its candidates obtain regulatory approval the company intends to commercialize them in the United States and other key markets through internal infrastructure or external partnerships. Until then Spyre’s customer base consists of investigators, study coordinators, and patients participating in its ongoing SKYLINE and SKYWAY trials.